Cargando…

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells

The oncolytic herpes simplex virus (HSV) that has been approved for clinical practice and those HSVs in clinical trials are attenuated viruses, often with the neurovirulence gene γ(1)34.5 and additional genes deleted. One strategy to engineer nonattenuated oncolytic HSVs consists of retargeting the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leoni, Valerio, Gatta, Valentina, Casiraghi, Costanza, Nicosia, Alfredo, Petrovic, Biljana, Campadelli-Fiume, Gabriella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Gene Delivery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5411604/ https://www.ncbi.nlm.nih.gov/pubmed/28250120 http://dx.doi.org/10.1128/JVI.00067-17

Ejemplares similares

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors
por: Leoni, Valerio, et al.
Publicado: (2018)

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells
por: Petrovic, Biljana, et al.
Publicado: (2018)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
por: Menotti, Laura, et al.
Publicado: (2018)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
por: Leoni, Valerio, et al.
Publicado: (2018)

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins
por: Petrovic, Biljana, et al.
Publicado: (2017)

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
por: Sasso, Emanuele, et al.
Publicado: (2020)

Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
por: Leoni, Valerio, et al.
Publicado: (2015)

Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line
por: Vannini, Andrea, et al.
Publicado: (2021)

A New Gorilla Adenoviral Vector with Natural Lung Tropism Avoids Liver Toxicity and Is Amenable to Capsid Engineering and Vector Retargeting
por: Lu, Zhi Hong, et al.
Publicado: (2020)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
por: Vannini, Andrea, et al.
Publicado: (2023)

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
por: De Lucia, Maria, et al.
Publicado: (2020)

The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors
por: Gatta, Valentina, et al.
Publicado: (2015)

Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)

Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus
por: Suzuki, Takuma, et al.
Publicado: (2021)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
por: Appolloni, Irene, et al.
Publicado: (2021)

Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
por: Gentile, Chiara, et al.
Publicado: (2021)

Oncolytic Foamy Virus: Generation and Properties of a Nonpathogenic Replicating Retroviral Vector System That Targets Chronically Proliferating Cancer Cells
por: Budzik, Karol M., et al.
Publicado: (2021)

Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome
por: Sam, Miranda, et al.
Publicado: (2023)

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV
por: Gianni, Tatiana, et al.
Publicado: (2021)

Generation of an Oncolytic Herpes Simplex Viral Vector Completely Retargeted to the GDNF Receptor GFRα1 for Specific Infection of Breast Cancer Cells
por: Hall, Bonnie L., et al.
Publicado: (2020)

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV
por: Vannini, Andrea, et al.
Publicado: (2021)

Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice
por: Di Scala, Marianna, et al.
Publicado: (2016)

Coevolution of Adeno-associated Virus Capsid Antigenicity and Tropism through a Structure-Guided Approach
por: Havlik, L. Patrick, et al.
Publicado: (2020)

Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product Development
por: Ballmann, Mónika Z., et al.
Publicado: (2021)

BST2 Suppresses LINE-1 Retrotransposition by Reducing the Promoter Activity of LINE-1 5′ UTR
por: Zhao, Yifei, et al.
Publicado: (2022)

Adeno-associated Virus (AAV) Capsid Chimeras with Enhanced Infectivity Reveal a Core Element in the AAV Genome Critical for both Cell Transduction and Capsid Assembly
por: Viney, Lydia, et al.
Publicado: (2021)

Characterization and biodistribution of under-employed gene therapy vector AAV7
por: Yost, Samantha A., et al.
Publicado: (2023)

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus
por: Froechlich, Guendalina, et al.
Publicado: (2020)

Retargeting of Viruses to Generate Oncolytic Agents
por: Verheije, M. H., et al.
Publicado: (2012)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_00969bo19uloepa6qdf4d5kl62